These 3 Stocks Aren't Large Caps Yet, but They Each Could Make $1 Billion in Sales in 2022
usx:pen usx:vir usx:clov Blog PostGlaxoSmithKline's and Vir's Latest COVID Therapy Results: What Investors Should Know
usx:gsk usx:vir Blog PostWhich Stock Is Likely to Be the Biggest Winner: Lilly, Vir, or GlaxoSmithKline?
usx:lly usx:gsk usx:vir Blog PostVir Biotechnology and GlaxoSmithKline Expand Their COVID Partnership to Flu
usx:gsk usx:vir Blog Post